OTC Markets OTCQB - Delayed Quote USD

Skinvisible, Inc. (SKVI)

0.2970

0.0000

(0.00%)

At close: January 29 at 3:00:00 PM EST

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant ...

ACCESS Newswire 7 days ago

QNRX

SKVI
0.00%
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), ...

ACCESS Newswire 6 months ago

SKVI
0.00%
Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research ...

ACCESS Newswire 7 months ago

SKVI
0.00%
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), ...

ACCESS Newswire 7 months ago

SKVI
0.00%
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX). The ...

ACCESS Newswire 11 months ago

SKVI
0.00%

Performance Overview

Return	SKVI	S&P 500
YTD	-11.87%	+2.78%
1-Year	+324.29%	+23.20%
3-Year	+90.87%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Skinvisible, Inc. (SKVI)

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Performance Overview